Articles by Claudia Balotta

Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure

Ceccherini-Silberstein, Francesca; Erba, Fulvio; Gago, Federico; More

AIDS. 18(12):11-19, August 20, 2004.

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy

Violin, Michela; Cozzi-Lepri, Alessandro; Velleca, Rossella; More

AIDS. 18(2):227-235, January 23, 2004.

Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors

Menzo, Stefano; Monachetti, Alessia; Balotta, Claudia; More

AIDS. 17(5):663-671, March 28, 2003.

Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation

Perno, Carlo Federico; Cozzi-Lepri, Alessandro; Balotta, Claudia; More

AIDS. 16(4):619-624, March 8, 2002.

Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy

Menzo, Stefano; Rusconi, Stefano; Monachetti, Alessia; More

AIDS. 14(9):1101-1110, June 16, 2000.

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral‐experienced patients in advanced stages of HIV‐1 infection

Monforte, Antonella d'Arminio; Testa, Letizia; Adorni, Fulvio; More

AIDS. 12(13):1631-1637, September 10, 1998.

Homozygous Δ32 deletion of the CCR‐5 chemokine receptor gene in an HIV‐1‐infected patient

Balotta, Claudia; Bagnarelli, Patrizia; Violin, Michela; More

AIDS. 11(10):F67-F71, August 11, 1997.